Bessemer Group’s Trevi Therapeutics TRVI Stock Holding History

Bessemer Group’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,560	Closed	-$20K	–	2690
2025 Q4	$20K	Buy	+1,560	New	+$18K	﹤0.01%	1884

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bessemer Group's TRVI Position: Q1 2026 in Review

Bessemer Group sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 1,560 shares — an estimated $20K sold.

Bessemer Group first reported a position in TRVI in Q4 2025 and held it in 1 quarter. The position peaked at $20K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Bessemer Group reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
Bessemer Group sold 1,560 Trevi Therapeutics shares in Q1 2026, an estimated $20K.
Bessemer Group first reported a position in Trevi Therapeutics in Q4 2025 and held it in 1 quarter.
Bessemer Group's Trevi Therapeutics position peaked at $20K in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.